Core Insights - Cumberland Pharmaceuticals Inc. has announced a strategic partnership with RedHill Biopharma Ltd. to jointly commercialize Talicia, an FDA-approved therapy for Helicobacter pylori infection, which is a significant risk factor for gastric cancer [1][2][3] Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on improving patient care through high-quality products, with a portfolio that includes various FDA-approved brands [7] - RedHill Biopharma is a specialty biopharmaceutical company primarily focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology [9] Partnership Details - The agreement involves forming a new jointly owned company where RedHill will contribute all Talicia assets, including international licenses and revenues, while Cumberland will invest $4 million and manage distribution and sales [2][4] - Talicia generated net revenues of $8 million in 2024, and both companies will share these revenues equally while collaborating on operational aspects such as sales, marketing, and supply chain [2][4] Product Information - Talicia is a unique all-in-one oral capsule combining omeprazole, amoxicillin, and rifabutin, with a high eradication rate of over 90%, simplicity of use, and low resistance [3][6] - The product is recognized as a first-line treatment option in the updated American College of Gastroenterology guidelines for H. pylori infections [3] Market Position - Talicia is patent-protected until 2042 and has received eight years of U.S. market exclusivity under the Qualified Infectious Disease Product (QIDP) designation [4][6] - The product has broad U.S. insurance coverage, with 70% of American lives covered by commercial plans and 60% by government plans, and is available at 1,700 CVS pharmacies [5]

Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company with a portfolio of FDA-approved branded products [6] - The company has three national sales divisions and several catalysts for new growth opportunities [6] - Cumberland has a proven record of successful product development and product acquisition [6] Product Portfolio - Acetadote is an IV treatment for acetaminophen overdose, developed and registered by Cumberland [11] - Caldolor is an injectable delivery of ibuprofen with antipyretic, analgesic & anti-inflammatory properties, approved for use in adults, children and newborns [15] - Kristalose is a unique crystalline formulation of lactulose, a prescription strength laxative [20] - Vibativ is an IV antibiotic that treats life-threatening infections resulting from gram-positive bacteria [24] - Sancuso is an FDA-approved transdermal system for chemotherapy-induced nausea and vomiting [29] - Ifetroban is Cumberland's first new chemical entity, a potent, selective antagonist of thromboxane receptor [30] Financial Performance (2024) - Net revenues were $37.9 million [51] - Gross profit was $31.3 million [51] - Adjusted earnings were $(1.0) million [51] - Cash and securities totaled $18.0 million as of December 31, 2024 [52] - The company has tax carryforward credits of $53 million available [52]